Treatment follow-up After 1 year, ICS (as ICS + LABA or triple therapy) was added for increased respiratory symptoms in 10/53 subjects (18.9%) and after 2 years in 12/41 patients (29.3%) with a clear trend but without any statistically significant difference among the time points considered: T6, T12, T18 and T24, Fig. 1 .
← all excerpts
Monitoring COPD patients: systemic and bronchial eosinophilic inflammation in a 2-year follow-up.
1
—
—